» Articles » PMID: 34981452

Mesenchymal Stem Cell Therapy for Osteoarthritis: Practice and Possible Promises

Overview
Date 2022 Jan 4
PMID 34981452
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA) is a common progressively degenerative joint disease that affects more than 300 million people worldwide. OA is manifested by articular cartilage degradation, chronic pain, deformity, functional disability, and decreased quality of life. A real challenge in OA management is the lack of an effective cure because exiting therapeutics often provide symptom control rather than disease modification; therefore, they fail to prevent disease progression. The inadequate treatments for OA management have encouraged researchers to study mesenchymal stem cells (MSCs) as an investigational treatment for OA. MSCs are a promising tool for OA because of their availability; expand cultivation and multi-lineage differentiation capacity as well as well-documented paracrine function have made MSCs a promising tool in this field. Accordingly, MSCs application has been successfully utilized in a broad range of pre-clinical OA animal models as well as clinical studies with the aim of cartilage repair which had not previously been achieved using classical treatments. Here, the brief scientific review of MSC role in the control of OA as well as the proposed mechanisms are discussed. We provide an insight into the last 10 years' studies conducted on preclinical and clinical OA treatment as well as future opportunities in OA management strategies employing MSCs.

Citing Articles

BMP-7 modified exosomes derived from synovial mesenchymal stem cells attenuate osteoarthritis by M2 polarization of macrophages.

Sun W, Qu S, Ji M, Sun Y, Hu B Heliyon. 2023; 9(9):e19934.

PMID: 37809369 PMC: 10559348. DOI: 10.1016/j.heliyon.2023.e19934.


Bibliometric and visualization analysis of mesenchymal stem cells and rheumatoid arthritis (from 2012 to 2021).

Liu J, Gao J, Niu Q, Wu F, Wu Z, Zhang L Front Immunol. 2022; 13:1001598.

PMID: 36311707 PMC: 9606664. DOI: 10.3389/fimmu.2022.1001598.

References
1.
Al Faqeh H, Nor Hamdan B, Chen H, Aminuddin B, Ruszymah B . The potential of intra-articular injection of chondrogenic-induced bone marrow stem cells to retard the progression of osteoarthritis in a sheep model. Exp Gerontol. 2012; 47(6):458-64. DOI: 10.1016/j.exger.2012.03.018. View

2.
Almeria C, Weiss R, Roy M, Tripisciano C, Kasper C, Weber V . Hypoxia Conditioned Mesenchymal Stem Cell-Derived Extracellular Vesicles Induce Increased Vascular Tube Formation . Front Bioeng Biotechnol. 2019; 7:292. PMC: 6819375. DOI: 10.3389/fbioe.2019.00292. View

3.
Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R . Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study. J Orthop Surg Res. 2017; 12(1):190. PMC: 5727956. DOI: 10.1186/s13018-017-0689-6. View

4.
Barron V, Merghani K, Shaw G, Coleman C, Hayes J, Ansboro S . Evaluation of Cartilage Repair by Mesenchymal Stem Cells Seeded on a PEOT/PBT Scaffold in an Osteochondral Defect. Ann Biomed Eng. 2015; 43(9):2069-82. DOI: 10.1007/s10439-015-1246-2. View

5.
Bastos R, Mathias M, Andrade R, Amaral R, Schott V, Balduino A . Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surg Sports Traumatol Arthrosc. 2019; 28(6):1989-1999. DOI: 10.1007/s00167-019-05732-8. View